Table 1.

Summary of relevant selected studies

Source	Country	Relevant information
Bressler NM et al. Arch Ophthalmol 2011 [6]	USA	Modeling on monthly ranibizumab/24 months: 2-year incidence of legal blindness − 72%, visual impairment − 37%
Skaat A et al. AJO 2012 [7]	Israel	Rate of blindness: 1999: 33.8/100000; 2008: 16.6/100000. − 51%
Bloch SB et al. AJO 2012 [8]	Denmark	Rate of blindness due to AMD: 2000: 52.2/100000; 2010: 25.7/100000. − 50%
Belkin M et al. AJO 2013 [9]	Israel	Rate of blindness: 2008: 16.6/100000; 2010: 14.8/100000
		Due to AMD: 2008: 3.51/10000; 2010: 2.84/100000
Borooah S et al. Eye 2015 [10]	Scotland	Incidence of legal blindness: 2006: 9.1/100000; 2011: 4.8/100000. − 47%
Rim TH et al. Clin Exp Ophthalmol 2017 [11]	South Korea	Incidence of blindness: 2002: 43.8/100000; 2013: 15.9/100000
Claessen et al. Graefes Arch Clin Exp Ophthalmol 2021 [12]	Saxony	Rate of blindness: 2009: 15.7/100000; 2017: 8.9/100000
		Due to AMD: 2009: 6.9/100000; 2017: 3.8/100000
		Due to DR: 2009: 1.5/100000; 2017: 0.7/100000
Heath Jeffery RC et al. Asia Pac J Ophthalmol 2021 [13]	Australia	Age-standardized annual incidence of blindness rose during the PDT era, reaching 72.5 cases per 100,000 person-years in 2004. The incidence declined from 2007 onwards, reaching 8.2 cases per 100,000 person-years in 2016 (IVT era)
Holz FG et al. BJO 2015 [14]	Multiple	Mean of 5.0 and 2.2 injections in the first and second year (Ireland 11, Canada 9.9, the UK 9, The Netherlands 8.7, France 6.3, Germany 5.6, Italy 5.2, Venezuela 3.2)

AMD, age-related macular degeneration; DR, diabetic retinopathy